RiboPro has raised $1.0M in total across 1 funding round.
RiboPro's investors include BOM Brabant Ventures.
RiboPro is a Netherlands-based CDMO specializing in high-quality mRNA production, LNP formulation, and related services for RNA-therapy pioneers in biotech, pharma, and academia.[1][2][3][7] It builds custom and off-the-shelf mRNA products, GMP-grade manufacturing, proprietary de-immunization tech, sequence optimization, and targeted LNP delivery systems to solve key challenges like mRNA instability, immunogenicity, inefficient delivery, and scalable production.[2][3][6][7] Serving researchers and developers advancing mRNA therapeutics and vaccines, RiboPro accelerates progression from R&D to clinical stages with industry-leading turnaround, deep expertise, and licensable technologies; the company has shown strong growth including 10x customer/revenue expansion, lab scaling, and hiring its 20th employee.[1][3]
RiboPro, founded in 2020 as a spin-off from Dutch biotech Mercurna, emerged from over a decade of hands-on mRNA synthesis and formulation experience by its scientist-founders at PivotPark in Oss, Netherlands.[1][2][4][6] The idea stemmed from a mission to democratize access to high-quality mRNA materials and breakthrough technologies, enabling global innovators to bring novel medicines to patients amid growing RNA-therapy demand.[1][5] Early milestones included filing its first mRNA modification patent, securing €1.3M seed funding from "smart money," a €3.5M Wellcome Leap R3-grant, rapid 10x growth in customers and revenue, lab expansion by 100m², team growth to 20 employees, and starting in-house enzyme production.[1]
RiboPro rides the explosive mRNA therapeutics wave, fueled by COVID-19 vaccines and projections that >90% of new medicines could be RNA-based in 20 years for enhanced safety/efficacy in ecology, health, and food challenges.[1][5] Timing is ideal post-pandemic, with market forces like surging demand for scalable, high-quality RNA tools amid supply bottlenecks favoring CDMOs; RiboPro influences the ecosystem by de-risking development for pioneers, enabling faster clinical translation via superior materials and IP.[3][7] Its PivotPark base and grants/partnerships amplify Dutch biotech hubs' global role in next-gen RNA innovation.[1][6]
RiboPro is poised for accelerated scaling with GMP expansion, in-house production ramps, and deepening partnerships in immunotherapy and beyond, potentially capturing share in the multi-billion mRNA CDMO market.[1][2][6] Trends like AI-optimized antibodies, non-liver targeted delivery, and broader RNA apps (e.g., environment/food) will shape its path, evolving its influence from service provider to key IP licensor powering blockbuster therapies.[3][5][6] As the premier partner for RNA pioneers, RiboPro exemplifies how specialized tech unlocks medicine's mRNA revolution.[1][7]
RiboPro has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $1.0M Seed | BOM Brabant Ventures |
